Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon

Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF

Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.

Thumbnail

Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke

All participants were free of ASCVD and had no history of statin use at the start of the study. 

Video of James Januzzi explaining the results of a new diabetic cardiomyopathy treatment in ACC 2024 late-breaking ARISE-HF trial. #ACC #ACC24 #ACC2024

Diabetic cardiomyopathy treatment shows promise in ARISE-HF

James Januzzi Jr., MD, said the treatment's overall impact was neutral, but he and his team saw "a very clear and encouraging signal."

Thumbnail

Keto diet ‘does not fulfill the criteria of a healthy diet,’ could be harmful for heart patients

The popular high-fat, low-carb diet is associated with multiple short-term benefits, but they appear to diminish over time. 

Bayer subsidiary granted FDA’s fast track designation for new congestive heart failure treatment

AskBio, acquired by Bayer for more than $2 billion in 2020, is enrolling patients for a new clinical trial focused on the therapy's effectiveness in adult patients with non-ischemic cardiomyopathy and heart failure. 

2 out of 5 AFib patients develop heart failure later in life

Stroke is typically seen as the biggest danger for patients after they receive an AFib diagnosis. This study, however, suggests heart failure could be an even bigger threat.

HeartMate 3 LVAD abbott

FDA announces new recall of Abbott’s HeartMate LVADs after 14 deaths

The issue at the center of this recall, which includes both the HeartMate II and HeartMate 3 LVAD, is the gradual buildup of biological materials. This can impact the device's performance, creating a heightened risk of injury or death. 

Video of Gregg Stone, MD, explaining the late-breaking RELIEVE-HF trial he presented at ACC.24 this week. #ACC24 #ACC2024

Inter-atrial shunt in RELIEVE-HF improves symptoms in HFrEF, but not HFpEF

Gregg Stone, MD, explains the details of the late-breaking RELIEVE-HF trial at ACC.24, where an inter-atrial shunt improved symptoms in HFrEF, but not in HFpEF patients.

Displaying 57 - 64 of 1270

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.